Zoe Doyle
Registered Nurse and Clinical Research Manager at University Health Network
Data updated
Papers
Trials
Research Footprint
Zoe Doyle appears in 9 tracked papers (2021–2026), most studied alongside Psilocybin and Ketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Anxiety Disorders.
Most-cited paper: Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin (89 citations).
Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Shokouh Meshkat.
Background & Research
Zoe Doyle appears as an author on several recent psychiatric and psychedelic medicine papers, including psilocybin-assisted psychotherapy studies for treatment-resistant depression and bipolar II disorder. She is listed as a contact at Toronto Western Hospital (University Health Network) and is identified in trial records as a registered nurse/clinical research manager involved in ongoing UHN psilocybin studies.
Key Impact
She is a recurring clinical research author on multiple psilocybin-assisted psychotherapy and ketamine/depression studies, indicating involvement in a notable Canadian psychedelic psychiatry research program.
Collaboration Network
15 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Zoe Doyle is associated with.
University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →University Health Network, Toronto
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
View stakeholder →